vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $194.8M, roughly 1.4× TOMPKINS FINANCIAL CORP). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs -45.7%, a 95.1% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 39.4%). TOMPKINS FINANCIAL CORP produced more free cash flow last quarter ($31.9M vs $-54.2M). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
GH vs TMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $194.8M |
| Net Profit | $-128.5M | $96.2M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 71.7% |
| Net Margin | -45.7% | 49.4% |
| Revenue YoY | 39.4% | 152.7% |
| Net Profit YoY | -15.8% | 388.9% |
| EPS (diluted) | $-1.01 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $194.8M | ||
| Q3 25 | $265.2M | $87.4M | ||
| Q2 25 | $232.1M | $82.6M | ||
| Q1 25 | $203.5M | $81.7M | ||
| Q4 24 | $201.8M | $77.1M | ||
| Q3 24 | $191.5M | $76.6M | ||
| Q2 24 | $177.2M | $72.7M | ||
| Q1 24 | $168.5M | $72.8M |
| Q4 25 | $-128.5M | $96.2M | ||
| Q3 25 | $-92.7M | $23.7M | ||
| Q2 25 | $-99.9M | $21.5M | ||
| Q1 25 | $-95.2M | $19.7M | ||
| Q4 24 | $-111.0M | $19.7M | ||
| Q3 24 | $-107.8M | $18.6M | ||
| Q2 24 | $-102.6M | $15.7M | ||
| Q1 24 | $-115.0M | $16.9M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 71.7% | ||
| Q3 25 | -37.3% | 35.6% | ||
| Q2 25 | -45.9% | 34.2% | ||
| Q1 25 | -54.6% | 31.6% | ||
| Q4 24 | -62.4% | 33.4% | ||
| Q3 24 | -61.3% | 32.0% | ||
| Q2 24 | -56.8% | 28.3% | ||
| Q1 24 | -59.2% | 30.4% |
| Q4 25 | -45.7% | 49.4% | ||
| Q3 25 | -35.0% | 27.1% | ||
| Q2 25 | -43.0% | 26.0% | ||
| Q1 25 | -46.8% | 24.1% | ||
| Q4 24 | -55.0% | 25.5% | ||
| Q3 24 | -56.3% | 24.3% | ||
| Q2 24 | -57.9% | 21.6% | ||
| Q1 24 | -68.2% | 23.2% |
| Q4 25 | $-1.01 | $6.72 | ||
| Q3 25 | $-0.74 | $1.65 | ||
| Q2 25 | $-0.80 | $1.50 | ||
| Q1 25 | $-0.77 | $1.37 | ||
| Q4 24 | $-0.90 | $1.39 | ||
| Q3 24 | $-0.88 | $1.30 | ||
| Q2 24 | $-0.84 | $1.10 | ||
| Q1 24 | $-0.94 | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $132.8M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $938.4M |
| Total Assets | $2.0B | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $132.8M | ||
| Q3 25 | $580.0M | $193.5M | ||
| Q2 25 | $629.1M | $212.6M | ||
| Q1 25 | $698.6M | $193.1M | ||
| Q4 24 | $525.5M | $134.4M | ||
| Q3 24 | $585.0M | $132.3M | ||
| Q2 24 | $933.7M | $70.9M | ||
| Q1 24 | $1.0B | $57.1M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $938.4M | ||
| Q3 25 | $-354.5M | $788.8M | ||
| Q2 25 | $-305.5M | $761.8M | ||
| Q1 25 | $-250.8M | $741.4M | ||
| Q4 24 | $-139.6M | $713.4M | ||
| Q3 24 | $-60.1M | $719.9M | ||
| Q2 24 | $-1.6M | $674.6M | ||
| Q1 24 | $68.3M | $667.9M |
| Q4 25 | $2.0B | $8.7B | ||
| Q3 25 | $1.3B | $8.5B | ||
| Q2 25 | $1.3B | $8.4B | ||
| Q1 25 | $1.3B | $8.2B | ||
| Q4 24 | $1.5B | $8.1B | ||
| Q3 24 | $1.5B | $8.0B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | $1.7B | $7.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $38.9M |
| Free Cash FlowOCF − Capex | $-54.2M | $31.9M |
| FCF MarginFCF / Revenue | -19.3% | 16.4% |
| Capex IntensityCapex / Revenue | 9.9% | 3.6% |
| Cash ConversionOCF / Net Profit | — | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $38.9M | ||
| Q3 25 | $-35.4M | $34.9M | ||
| Q2 25 | $-60.3M | $18.9M | ||
| Q1 25 | $-62.7M | $22.2M | ||
| Q4 24 | $-64.5M | $95.0M | ||
| Q3 24 | $-51.1M | $21.2M | ||
| Q2 24 | $-94.0M | $27.3M | ||
| Q1 24 | $-30.3M | $23.2M |
| Q4 25 | $-54.2M | $31.9M | ||
| Q3 25 | $-45.8M | $33.9M | ||
| Q2 25 | $-65.9M | $18.3M | ||
| Q1 25 | $-67.1M | $20.9M | ||
| Q4 24 | $-83.4M | $88.8M | ||
| Q3 24 | $-55.3M | $18.9M | ||
| Q2 24 | $-99.1M | $26.3M | ||
| Q1 24 | $-37.2M | $21.9M |
| Q4 25 | -19.3% | 16.4% | ||
| Q3 25 | -17.3% | 38.8% | ||
| Q2 25 | -28.4% | 22.1% | ||
| Q1 25 | -33.0% | 25.5% | ||
| Q4 24 | -41.3% | 115.1% | ||
| Q3 24 | -28.9% | 24.7% | ||
| Q2 24 | -55.9% | 36.2% | ||
| Q1 24 | -22.1% | 30.0% |
| Q4 25 | 9.9% | 3.6% | ||
| Q3 25 | 3.9% | 1.1% | ||
| Q2 25 | 2.4% | 0.8% | ||
| Q1 25 | 2.2% | 1.7% | ||
| Q4 24 | 9.4% | 8.1% | ||
| Q3 24 | 2.2% | 2.9% | ||
| Q2 24 | 2.9% | 1.3% | ||
| Q1 24 | 4.1% | 1.9% |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 4.82× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.74× | ||
| Q1 24 | — | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
TMP
Segment breakdown not available.
